Linong Ji1, Fabrice Bonnet2, Bernard Charbonnel3, Marilia B Gomes4, Mikhail Kosiborod5, Kamlesh Khunti6, Antonio Nicolucci7, Stuart Pocock8, Wolfgang Rathmann9, Marina V Shestakova10, Iichiro Shimomura11, Hirotaka Watada12, Peter Fenici13, Niklas Hammar14, Kiyoshi Hashigami15, Greg Macaraeg16, Filip Surmont16, Jesús Medina17. 1. Peking University People's Hospital, Beijing, China. Electronic address: jilinong@gmail.com. 2. Rennes University Hospital, Rennes, France. 3. University of Nantes, Nantes, France. 4. Rio de Janeiro State University, Rio de Janeiro, Brazil. 5. Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri, Kansas City, MO, USA. 6. University of Leicester, Leicester, UK. 7. Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. 8. London School of Hygiene and Tropical Medicine, London, UK. 9. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University, Düsseldorf, Germany. 10. Endocrinology Research Center, Diabetes Institute, Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation. 11. Graduate School of Medicine, Osaka University, Osaka, Japan. 12. Graduate School of Medicine, Juntendo University, Tokyo, Japan. 13. AstraZeneca, Cambridge, UK. 14. AstraZeneca, Mölndal, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 15. AstraZeneca, Tokyo, Japan. 16. AstraZeneca, Wilmington, DE, USA. 17. AstraZeneca, Madrid, Spain.
Abstract
AIM: Contemporary global real-world data on the management of type 2 diabetes are scarce. The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice. METHODS: The DISCOVER program comprises two longitudinal observational studies involving more than 15,000 patients in 38 countries across six continents. Study sites have been selected to be representative of type 2 diabetes management in each country. Data will be collected at baseline (initiation of second-line therapy), at 6months, and yearly during a 3-year follow-up period. RESULTS: The DISCOVER program will record patient, healthcare provider, and healthcare system characteristics, treatment patterns, and factors influencing changes in therapy. In addition, disease control (e.g. achievement of glycated hemoglobin target), management of associated risk factors (e.g. hypercholesterolemia and hypertension), and healthcare resource utilization will be recorded. Microvascular and macrovascular complications, incidence of hypoglycemic events, and patient-reported outcomes will also be captured. CONCLUSIONS: The DISCOVER program will provide insights into the current management of patients with type 2 diabetes worldwide, which will contribute to informing future clinical guidelines and improving patient care.
AIM: Contemporary global real-world data on the management of type 2 diabetes are scarce. The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice. METHODS: The DISCOVER program comprises two longitudinal observational studies involving more than 15,000 patients in 38 countries across six continents. Study sites have been selected to be representative of type 2 diabetes management in each country. Data will be collected at baseline (initiation of second-line therapy), at 6months, and yearly during a 3-year follow-up period. RESULTS: The DISCOVER program will record patient, healthcare provider, and healthcare system characteristics, treatment patterns, and factors influencing changes in therapy. In addition, disease control (e.g. achievement of glycated hemoglobin target), management of associated risk factors (e.g. hypercholesterolemia and hypertension), and healthcare resource utilization will be recorded. Microvascular and macrovascular complications, incidence of hypoglycemic events, and patient-reported outcomes will also be captured. CONCLUSIONS: The DISCOVER program will provide insights into the current management of patients with type 2 diabetes worldwide, which will contribute to informing future clinical guidelines and improving patient care.
Authors: Kamlesh Khunti; Thomas R Godec; Jesús Medina; Laura Garcia-Alvarez; Josh Hiller; Marilia B Gomes; Javier Cid-Ruzafa; Bernard Charbonnel; Peter Fenici; Niklas Hammar; Kiyoshi Hashigami; Mikhail Kosiborod; Antonio Nicolucci; Marina V Shestakova; Linong Ji; Stuart Pocock Journal: Diabetes Obes Metab Date: 2017-09-28 Impact factor: 6.577
Authors: Stéphane Pintat; Peter Fenici; Niklas Hammar; Linong Ji; Kamlesh Khunti; Jesús Medina; Fengming Tang; Eric Wittbrodt; Filip Surmont Journal: BMJ Open Diabetes Res Care Date: 2019-03-21
Authors: Kamlesh Khunti; Marilia B Gomes; Mikhail Kosiborod; Antonio Nicolucci; Stuart Pocock; Wolfgang Rathmann; Marina V Shestakova; Iichiro Shimomura; Hirotaka Watada; Hungta Chen; Javier Cid-Ruzafa; Peter Fenici; Niklas Hammar; Fengming Tang; Linong Ji Journal: BMJ Open Date: 2020-08-30 Impact factor: 2.692